• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

France expands reimbursement for Abbott FreeStyle Libre 2 to all basal insulin users

June 22, 2023 By Sean Whooley

Abbott FreeStyle Libre 2
The FreeStyle Libre 2 continuous glucose monitor (CGM). [Image from Abbott]
Abbott (NYSE:ABT) announced today that the French health authority approved the expansion of reimbursement coverage for the FreeStyle Libre 2.

FreeStyle Libre 2 previously only had coverage for people with type 1 and type 2 diabetes who require intensive insulin therapy. France’s expansion covers the continuous glucose monitor (CGM) for all people who use basal insulin as part of their diabetes management.

The Abbott Park, Illinois-based company said this expansion enables more access to the CGM in France. Abbott noted that more than 90% of people living with diabetes in France have type 2.

France’s expansion marks the first European widening of national reimbursement for FreeStyle Libre to basal insulin users. It follows similar coverage changes in Japan and the U.S. Medicare system. According to Abbott, altogether, it expands eligibility to 3 million more people living with diabetes.

“Our goal is to get our FreeStyle Libre technology to as many people as possible,” said Jared Watkin, SVP of Abbott’s diabetes care business. “The French national reimbursement decision is an important step in providing broader access to people with diabetes, and we are working with other countries to extend this coverage to more people.”

Clinical evidence supported coverage expansion for Abbott technology

Abbott said it received the coverage decision based on scientific evidence supporting FreeStyle Libre’s clinical benefits for insulin users. That includes the Real World Evidence of FreeStyle Libre (RELIEF) study.

This retrospective study of the French national claims database showed significant reductions in acute complications of diabetes for those with type 2 on once-daily basal insulin. It led to a 67% decrease in hospitalizations.

“Studies have shown that FreeStyle Libre technology can help people with diabetes improve their glucose control, decrease diabetes-related hospital admissions, and reduce the burden associated with conventional self-monitoring of blood glucose,” said Professor Bruno Guerci, Department of Endocrinology, Diabetology, and Nutrition at Brabois Adult Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France. “The expanded reimbursement for Abbott’s FreeStyle Libre 2 now opens up access to allow a new group of patients to experience the benefits of continuous glucose monitoring, which was only available to those with type 1 or type 2 diabetes and following intensive insulin therapy.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Regulatory/Compliance, Technology Tagged With: abbott, ADA 2023

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS